Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer.

de Weger VA, Turksma AW, Voorham QJ, Euler Z, Bril H, van den Eertwegh AJ, Bloemena E, Pinedo HM, Vermorken JB, van Tinteren H, Meijer GA, Hooijberg E.

Clin Cancer Res. 2012 Feb 1;18(3):882-9. doi: 10.1158/1078-0432.CCR-11-1716. Epub 2011 Dec 12.

2.

Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits.

Uyl-de Groot CA, Vermorken JB, Hanna MG Jr, Verboom P, Groot MT, Bonsel GJ, Meijer CJ, Pinedo HM.

Vaccine. 2005 Mar 18;23(17-18):2379-87.

PMID:
15755632
3.

Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.

Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, de Jong D, ter Elst A, Mulder NH, Buys CH, Hofstra RM, Plukker JT.

J Clin Oncol. 2005 Aug 20;23(24):5635-43.

PMID:
16110022
4.

Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific Immunotherapy.

Turksma AW, Coupé VM, Shamier MC, Lam KL, de Weger VA, Belien JA, van den Eertwegh AJ, Meijer GA, Meijer CJ, Hooijberg E.

Clin Cancer Res. 2016 Jan 15;22(2):346-56. doi: 10.1158/1078-0432.CCR-13-2462. Epub 2015 Sep 29.

5.

Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence.

Belt EJ, Fijneman RJ, van den Berg EG, Bril H, Delis-van Diemen PM, Tijssen M, van Essen HF, de Lange-de Klerk ES, Beliën JA, Stockmann HB, Meijer S, Meijer GA.

Eur J Cancer. 2011 Aug;47(12):1837-45. doi: 10.1016/j.ejca.2011.04.025. Epub 2011 May 27.

6.

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.

Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MG Jr, Pinedo HM.

Lancet. 1999 Jan 30;353(9150):345-50.

PMID:
9950438
7.

Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator for adjuvant therapy in colon cancer.

Kumar S, Chang EY, Frankhouse J, Dorsey PB, Lee RG, Johnson N.

Arch Surg. 2009 Sep;144(9):835-40. doi: 10.1001/archsurg.2009.162.

PMID:
19797108
8.

Low microsatellite instability is associated with poor prognosis in stage C colon cancer.

Kohonen-Corish MR, Daniel JJ, Chan C, Lin BP, Kwun SY, Dent OF, Dhillon VS, Trent RJ, Chapuis PH, Bokey EL.

J Clin Oncol. 2005 Apr 1;23(10):2318-24.

PMID:
15800322
9.

High lymph node yield is related to microsatellite instability in colon cancer.

Belt EJ, te Velde EA, Krijgsman O, Brosens RP, Tijssen M, van Essen HF, Stockmann HB, Bril H, Carvalho B, Ylstra B, Bonjer HJ, Meijer GA.

Ann Surg Oncol. 2012 Apr;19(4):1222-30. doi: 10.1245/s10434-011-2091-7. Epub 2011 Oct 12.

10.

Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.

Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS.

Cancer Chemother Pharmacol. 2010 Sep;66(4):659-67. doi: 10.1007/s00280-009-1206-3. Epub 2009 Dec 24.

PMID:
20033812
11.
12.

[Microsatellite instability and therapeutic sensitivity].

Jung A.

Verh Dtsch Ges Pathol. 2007;91:112-8. German.

PMID:
18314604
13.

Microsatellite instability did not predict individual survival in sporadic stage II and III rectal cancer patients.

Meng WJ, Sun XF, Tian C, Wang L, Yu YY, Zhou B, Gu J, Xia QJ, Li Y, Wang R, Zheng XL, Zhou ZG.

Oncology. 2007;72(1-2):82-8. Epub 2007 Nov 14.

PMID:
18004081
14.

Chromosomal instability in microsatellite-unstable and stable colon cancer.

Trautmann K, Terdiman JP, French AJ, Roydasgupta R, Sein N, Kakar S, Fridlyand J, Snijders AM, Albertson DG, Thibodeau SN, Waldman FM.

Clin Cancer Res. 2006 Nov 1;12(21):6379-85.

15.

Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.

Klingbiel D, Saridaki Z, Roth AD, Bosman FT, Delorenzi M, Tejpar S.

Ann Oncol. 2015 Jan;26(1):126-32. doi: 10.1093/annonc/mdu499. Epub 2014 Oct 30.

PMID:
25361982
16.

Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor.

Dahlin AM, Henriksson ML, Van Guelpen B, Stenling R, Oberg A, Rutegård J, Palmqvist R.

Mod Pathol. 2011 May;24(5):671-82. doi: 10.1038/modpathol.2010.234. Epub 2011 Jan 14.

17.

Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.

Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, Allegra CJ; National Cancer Institute.

J Clin Oncol. 2007 Mar 1;25(7):767-72. Epub 2007 Jan 16.

PMID:
17228023
18.

Microsatellite instability in solitary and sporadic gastric cancer.

Perez RO, Jacob CE, D'Ottaviano FL, Alvarenga C, Ribeiro AS, Ribeiro U Jr, Bresciani CJ, Zilberstein B, Krieger JE, Habr-Gama A, Gama-Rodrigues JJ.

Rev Hosp Clin Fac Med Sao Paulo. 2004 Oct;59(5):279-85. Epub 2004 Oct 29.

19.

Screening for microsatellite instability identifies frequent 3'-untranslated region mutation of the RB1-inducible coiled-coil 1 gene in colon tumors.

Paun BC, Cheng Y, Leggett BA, Young J, Meltzer SJ, Mori Y.

PLoS One. 2009 Nov 2;4(11):e7715. doi: 10.1371/journal.pone.0007715.

20.

CIMP status of interval colon cancers: another piece to the puzzle.

Arain MA, Sawhney M, Sheikh S, Anway R, Thyagarajan B, Bond JH, Shaukat A.

Am J Gastroenterol. 2010 May;105(5):1189-95. doi: 10.1038/ajg.2009.699. Epub 2009 Dec 15.

PMID:
20010923

Supplemental Content

Support Center